Clinical Trials Mesothelioma - Revision history

MesotheliomaSupport: Fix stale phone numbers → (855) 699-5441 (ALFRED 2026-05-14)

2026-05-14T23:25:06Z

Fix stale phone numbers → (855) 699-5441 (ALFRED 2026-05-14)

← Older revision		Revision as of 23:25, 14 May 2026
Line 1,072:		Line 1,072:
	'''Call Danziger & De Llano for a free, confidential case review:'''		'''Call Danziger & De Llano for a free, confidential case review:'''

	<span style="font-size:1.5em; font-weight:bold;">(~~866~~) ~~222~~-~~9990~~</span>		<span style="font-size:1.5em; font-weight:bold;">(855) 699-5441</span>

	[https://dandell.com/contact-us/ Click Here for a Free Case Review]		[https://dandell.com/contact-us/ Click Here for a Free Case Review]
Line 1,276:		Line 1,276:
	Mesothelioma patients and families seeking clinical trial guidance can connect with experienced advocates:		Mesothelioma patients and families seeking clinical trial guidance can connect with experienced advocates:

	* [https://dandell.com/contact-us/ Danziger & De Llano] provides free case evaluations and can connect families with specialized mesothelioma treatment centers offering clinical trials — call (~~866~~) ~~222~~-~~9990~~		* [https://dandell.com/contact-us/ Danziger & De Llano] provides free case evaluations and can connect families with specialized mesothelioma treatment centers offering clinical trials — call (855) 699-5441
	* [https://www.mesotheliomalawyercenter.org/mesothelioma/ Mesothelioma Lawyer Center] offers resources on treatment options, clinical trials, and legal rights for asbestos exposure		* [https://www.mesotheliomalawyercenter.org/mesothelioma/ Mesothelioma Lawyer Center] offers resources on treatment options, clinical trials, and legal rights for asbestos exposure
	* [https://mesothelioma.net/mesothelioma/ Mesothelioma.net] provides comprehensive information on mesothelioma clinical trials, treatment, and prognosis		* [https://mesothelioma.net/mesothelioma/ Mesothelioma.net] provides comprehensive information on mesothelioma clinical trials, treatment, and prognosis

MesotheliomaSupport: RON: Add OG/Twitter meta — type=Article, twitter_card=summary_large_image

2026-04-25T14:15:26Z

RON: Add OG/Twitter meta — type=Article, twitter_card=summary_large_image

← Older revision		Revision as of 14:15, 25 April 2026
Line 6:		Line 6:
	\|author=Anna Jackson, Client Advocate, Danziger & De Llano		\|author=Anna Jackson, Client Advocate, Danziger & De Llano
	\|published_time=2026-04-13		\|published_time=2026-04-13
	}}		\|type=Article
			\|twitter_card=summary_large_image}}

	{\| class="infobox" style="width:280px; float:right; margin:0 0 1em 1em; border:2px solid #1a5276; border-radius:8px; overflow:hidden;"		{\| class="infobox" style="width:280px; float:right; margin:0 0 1em 1em; border:2px solid #1a5276; border-radius:8px; overflow:hidden;"

MesotheliomaSupport: Add At-a-Glance section per template standard

2026-04-23T20:10:14Z

Add At-a-Glance section per template standard

← Older revision		Revision as of 20:10, 23 April 2026
Line 53:		Line 53:

	Three systemic therapy regimens are now FDA-approved for malignant pleural mesothelioma: cisplatin plus pemetrexed (approved 2004),<ref name="vogelzang-2003">[https://pubmed.ncbi.nlm.nih.gov/12860938/ Vogelzang NJ et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma], ''Journal of Clinical Oncology'', 2003</ref> nivolumab plus ipilimumab (approved October 2020),<ref name="checkmate-743">[https://pubmed.ncbi.nlm.nih.gov/33485464/ Baas P et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial], ''The Lancet'', 2021</ref> and pembrolizumab plus pemetrexed plus platinum chemotherapy (approved September 17, 2024).<ref name="keynote-483">[https://pubmed.ncbi.nlm.nih.gov/37931632/ Chu Q et al. Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial], ''The Lancet'', November 2023</ref><ref name="fda-pembro">[https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-chemotherapy-unresectable-advanced-or-metastatic-malignant-pleural FDA Approves Pembrolizumab with Chemotherapy for Malignant Pleural Mesothelioma], FDA.gov, September 2024</ref> The most significant recent milestone is the CheckMate 743 five-year update, published in the ''Journal of Clinical Oncology'' in February 2026, confirming that nivolumab plus ipilimumab achieves a '''14% five-year overall survival rate versus 6% with chemotherapy''' (HR 0.74, 95% CI 0.62-0.88).<ref name="checkmate-5yr">[https://ascopubs.org/doi/10.1200/JCO-25-01328 Scherpereel A et al. Five-year overall survival update from CheckMate 743: nivolumab plus ipilimumab versus chemotherapy in first-line unresectable malignant pleural mesothelioma], ''Journal of Clinical Oncology'', February 2026</ref> In non-epithelioid disease, the five-year survival gap was even more dramatic: '''12% versus 1%''' (HR 0.48), representing one of the most significant survival benefits reported in this historically treatment-resistant subgroup.<ref name="checkmate-5yr" />		Three systemic therapy regimens are now FDA-approved for malignant pleural mesothelioma: cisplatin plus pemetrexed (approved 2004),<ref name="vogelzang-2003">[https://pubmed.ncbi.nlm.nih.gov/12860938/ Vogelzang NJ et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma], ''Journal of Clinical Oncology'', 2003</ref> nivolumab plus ipilimumab (approved October 2020),<ref name="checkmate-743">[https://pubmed.ncbi.nlm.nih.gov/33485464/ Baas P et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial], ''The Lancet'', 2021</ref> and pembrolizumab plus pemetrexed plus platinum chemotherapy (approved September 17, 2024).<ref name="keynote-483">[https://pubmed.ncbi.nlm.nih.gov/37931632/ Chu Q et al. Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial], ''The Lancet'', November 2023</ref><ref name="fda-pembro">[https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-chemotherapy-unresectable-advanced-or-metastatic-malignant-pleural FDA Approves Pembrolizumab with Chemotherapy for Malignant Pleural Mesothelioma], FDA.gov, September 2024</ref> The most significant recent milestone is the CheckMate 743 five-year update, published in the ''Journal of Clinical Oncology'' in February 2026, confirming that nivolumab plus ipilimumab achieves a '''14% five-year overall survival rate versus 6% with chemotherapy''' (HR 0.74, 95% CI 0.62-0.88).<ref name="checkmate-5yr">[https://ascopubs.org/doi/10.1200/JCO-25-01328 Scherpereel A et al. Five-year overall survival update from CheckMate 743: nivolumab plus ipilimumab versus chemotherapy in first-line unresectable malignant pleural mesothelioma], ''Journal of Clinical Oncology'', February 2026</ref> In non-epithelioid disease, the five-year survival gap was even more dramatic: '''12% versus 1%''' (HR 0.48), representing one of the most significant survival benefits reported in this historically treatment-resistant subgroup.<ref name="checkmate-5yr" />

			== At-a-Glance ==

	'''Mesothelioma clinical trials at a glance:'''		'''Mesothelioma clinical trials at a glance:'''
Line 114:		Line 116:
	\| style="padding:10px;" \| Phase I recruiting<ref name="ism6331" />		\| style="padding:10px;" \| Phase I recruiting<ref name="ism6331" />
	\|}		\|}



	== What Are Mesothelioma Clinical Trials? ==		== What Are Mesothelioma Clinical Trials? ==

MesotheliomaSupport: CLEO QA 90/100 PASS: keynote-483 country fix, Get Help section added (commit 2cedf65)

2026-04-20T23:35:43Z

CLEO QA 90/100 PASS: keynote-483 country fix, Get Help section added (commit 2cedf65)

Show changes

MesotheliomaSupport: Remove mesotheliomahelp.org blocked domain row from resource table (CLEO #1327)

2026-04-14T14:05:44Z

Remove mesotheliomahelp.org blocked domain row from resource table (CLEO #1327)

← Older revision		Revision as of 14:05, 14 April 2026
Line 774:		Line 774:
	\| style="padding:10px; border-bottom:1px solid #dee2e6;" \| [https://www.cancer.gov/about-cancer/treatment/clinical-trials/search cancer.gov]		\| style="padding:10px; border-bottom:1px solid #dee2e6;" \| [https://www.cancer.gov/about-cancer/treatment/clinical-trials/search cancer.gov]
	\| style="padding:10px; border-bottom:1px solid #dee2e6;" \| Patient-friendly interface; 12,000+ trials; NCI-sponsored trial detail<ref name="nci-cancer-gov" />		\| style="padding:10px; border-bottom:1px solid #dee2e6;" \| Patient-friendly interface; 12,000+ trials; NCI-sponsored trial detail<ref name="nci-cancer-gov" />
	\|-
	~~\| style="padding:10px; border-bottom:1px solid #dee2e6;" \| MesotheliomaHelp.org~~
	~~\| style="padding:10px; border-bottom:1px solid #dee2e6;" \| [https://www.mesotheliomahelp.org mesotheliomahelp.org]~~
	\| style="padding:10px; border-bottom:1px solid #dee2e6;" \| First database solely for mesothelioma (launched December 2025); searchable by subtype and location<ref name="mesohelp">[https://www.mesotheliomahelp.org MesotheliomaHelp.org Clinical Trials Search Tool], MesotheliomaHelp.org, December 2025</ref>
	\|-		\|-
	\| style="padding:10px;" \| MesoRFA.org		\| style="padding:10px;" \| MesoRFA.org

MesotheliomaSupport: Remove blocked domains: mesowatch.org ref replaced with ClinicalTrials.gov, curemeso.org rows removed from resource and financial tables

2026-04-14T12:31:29Z

Remove blocked domains: mesowatch.org ref replaced with ClinicalTrials.gov, curemeso.org rows removed from resource and financial tables

Show changes

MesotheliomaSupport: Remove blocked domain citations (MesoWatch, MesotheliomaHelp, CureMeso/MARF) — replaced with ClinicalTrials.gov

2026-04-13T18:26:25Z

Remove blocked domain citations (MesoWatch, MesotheliomaHelp, CureMeso/MARF) — replaced with ClinicalTrials.gov

Show changes

MesotheliomaSupport: New page: Clinical Trials Mesothelioma — CLEO QA 89/100, deployed by claude-home

2026-04-13T17:05:48Z

New page: Clinical Trials Mesothelioma — CLEO QA 89/100, deployed by claude-home

Show changes

← Older revision		Revision as of 14:05, 14 April 2026
Line 774:		Line 774:
	\| style="padding:10px; border-bottom:1px solid #dee2e6;" \| [https://www.cancer.gov/about-cancer/treatment/clinical-trials/search cancer.gov]		\| style="padding:10px; border-bottom:1px solid #dee2e6;" \| [https://www.cancer.gov/about-cancer/treatment/clinical-trials/search cancer.gov]
	\| style="padding:10px; border-bottom:1px solid #dee2e6;" \| Patient-friendly interface; 12,000+ trials; NCI-sponsored trial detail<ref name="nci-cancer-gov" />		\| style="padding:10px; border-bottom:1px solid #dee2e6;" \| Patient-friendly interface; 12,000+ trials; NCI-sponsored trial detail<ref name="nci-cancer-gov" />
	\|-
	~~\| style="padding:10px; border-bottom:1px solid #dee2e6;" \| MesotheliomaHelp.org~~
	~~\| style="padding:10px; border-bottom:1px solid #dee2e6;" \| [https://www.mesotheliomahelp.org mesotheliomahelp.org]~~
	\| style="padding:10px; border-bottom:1px solid #dee2e6;" \| First database solely for mesothelioma (launched December 2025); searchable by subtype and location<ref name="mesohelp">[https://www.mesotheliomahelp.org MesotheliomaHelp.org Clinical Trials Search Tool], MesotheliomaHelp.org, December 2025</ref>
	\|-		\|-
	\| style="padding:10px;" \| MesoRFA.org		\| style="padding:10px;" \| MesoRFA.org